quinazolines has been researched along with alovudine in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 10 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Atkinson, DM; Carlson, BL; Clarke, MJ; Jacobson, MS; Kemp, BJ; Lowe, VJ; Mladek, AC; Sarkaria, JN; Trump, DP | 1 |
| Backes, H; Borgman, CL; Jacobs, AH; Koker, M; Li, H; Neumaier, B; Shapiro, GI; Shimamura, T; Sos, ML; Tawadros, S; Thomas, RK; Ullrich, RT; Waerzeggers, Y; Winkeler, A; Wolf, J; Zander, T | 1 |
| Binns, DS; Callahan, J; Conti, P; Fine, BM; Hicks, RJ; Macfarlane, D; Mileshkin, L; Pirzkall, A; Scott, AM; Yu, W | 1 |
| Banerjee, D; Bertino, JR; Blasberg, RG; Cai, S; de Stanchina, E; Kochetkov, T; Moroz, MA; Nair, J; Schwartz, GK; Serganova, I; Shamis, M; Wu, J | 1 |
| Boellaard, R; Buettner, R; Dietlein, M; Draube, A; Engel-Riedel, W; Hallek, M; Hellmich, M; Heukamp, L; Jacobs, AH; Ko, YD; Kobe, C; Lammertsma, AA; Neumaier, B; Nogova, L; Papachristou, I; Querings, S; Scheffler, M; Schlesinger, A; Schulte, K; Smit, E; Stoelben, E; Thomas, RK; Toepelt, K; Ullrich, RT; Wolf, J; Zander, T | 1 |
| Boellaard, R; Dietlein, M; Holstein, A; Kahraman, D; Kobe, C; Lammertsma, AA; Neumaier, B; Nogova, L; Scheffler, M; Ullrich, RT; Wolf, J; Zander, T | 2 |
| Del Vecchio, S; Iommelli, F; Salvatore, M; Speranza, A; Zannetti, A | 1 |
| Dietlein, M; Kahraman, D; Kobe, C; Neumaier, B; Nogova, L; Scheffler, M; Thomas, R; Wolf, J; Zander, T | 1 |
| Boellaard, R; Dietlein, M; Holstein, A; Kahraman, D; Kobe, C; Lammertsma, AA; Neumaier, B; Nogova, L; Scheffler, M; Wolf, J; Zander, T | 1 |
| Boellaard, R; Büttner, R; Dietlein, M; Engel-Riedel, W; Heukamp, L; Kahraman, D; Kobe, C; Lammertsma, AA; Neumaier, B; Nogova, L; Papachristou, I; Querings, S; Scheffler, M; Stoelben, E; Wolf, J; Zander, T | 1 |
| Frechen, S; Fuhr, U; Kahraman, D; Kobe, C; Nogova, L; Scheffler, M; Suleiman, AA; Wolf, J; Zander, T | 1 |
6 trial(s) available for quinazolines and alovudine
| Article | Year |
|---|---|
Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer.
Topics: Biological Transport; Blood Glucose; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Erlotinib Hydrochloride; Feasibility Studies; Fluorodeoxyglucose F18; Guideline Adherence; Humans; Internationality; Lung Neoplasms; Positron-Emission Tomography; Quality Control; Quinazolines; Treatment Outcome | 2011 |
Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Positron-Emission Tomography; Prognosis; Quinazolines | 2011 |
Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
Topics: Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Neoplasm Staging; Positron-Emission Tomography; Quinazolines; Time Factors; Treatment Outcome | 2011 |
Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinib.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Dideoxynucleosides; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Quinazolines; Treatment Outcome | 2012 |
Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung; Lung Neoplasms; Male; Middle Aged; Mutation; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2013 |
Modeling tumor dynamics and overall survival in advanced non-small-cell lung cancer treated with erlotinib.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Dideoxynucleosides; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Survival Analysis | 2015 |
6 other study(ies) available for quinazolines and alovudine
| Article | Year |
|---|---|
Using fluorodeoxythymidine to monitor anti-EGFR inhibitor therapy in squamous cell carcinoma xenografts.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Dideoxynucleosides; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorine Radioisotopes; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines | 2008 |
Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET).
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Dideoxynucleosides; Down-Regulation; Early Detection of Cancer; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Ki-67 Antigen; Lung Neoplasms; Mice; Positron-Emission Tomography; Quinazolines; Signal Transduction; Treatment Outcome; Xenograft Model Antitumor Assays | 2008 |
Imaging colon cancer response following treatment with AZD1152: a preclinical analysis of [18F]fluoro-2-deoxyglucose and 3'-deoxy-3'-[18F]fluorothymidine imaging.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Dideoxynucleosides; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Fluorouracil; HCT116 Cells; Humans; Immunoblotting; Ki-67 Antigen; Methotrexate; Mice; Mice, Nude; Organophosphates; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Thymidine; Thymidine Kinase; Xenograft Model Antitumor Assays | 2011 |
3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; bcl-X Protein; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dideoxynucleosides; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Image Processing, Computer-Assisted; Lung Neoplasms; Mice; Mice, Inbred BALB C; Multimodal Imaging; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Sulfonamides; Tomography, X-Ray Computed | 2012 |
Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Discriminant Analysis; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Predictive Value of Tests; Quinazolines; Radiopharmaceuticals; Retrospective Studies; ROC Curve | 2012 |
Monitoring reversible and irreversible EGFR inhibition with erlotinib and afatinib in a patient with EGFR-mutated non-small cell lung cancer (NSCLC) using sequential [18F]fluorothymidine (FLT-)PET.
Topics: Adenocarcinoma; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dideoxynucleosides; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Neoplasms; Quinazolines; Radionuclide Imaging; Radiopharmaceuticals; Sequence Deletion | 2012 |